Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.

Jen-Jung Pan; Milind Javle; Mie Mie Thinn; Chung-Tzu Hsueh; Chung-Tsen Hsueh

doi:10.2147/HMER.S7123

Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.

Jen-Jung Pan
, Milind Javle
, Mie Mie Thinn
, Chung-Tzu Hsueh
, Chung-Tsen Hsueh

Research output: Contribution to journal › Review article › peer-review

Abstract

Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.

Original language	American English
Pages (from-to)	147-55
Number of pages	9
Journal	Hepatic Medicine : Evidence and Research
Volume	2
DOIs	https://doi.org/10.2147/HMER.S7123
State	Published - Nov 2 2010

Disciplines

Virology
Alternative and Complementary Medicine
Medicine and Health Sciences
Oncology
Internal Medicine
Endocrinology, Diabetes, and Metabolism

Access to Document

10.2147/HMER.S7123License: Unspecified

OpenUrl availability

Full text

Cite this

@article{38f1106063824e4e97530e4f4961bcad,

title = "Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.",

abstract = "Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44\% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.",

author = "Jen-Jung Pan and Milind Javle and Thinn, \{Mie Mie\} and Chung-Tzu Hsueh and Chung-Tsen Hsueh",

year = "2010",

month = nov,

day = "2",

doi = "10.2147/HMER.S7123",

language = "American English",

volume = "2",

pages = "147--55",

journal = "Hepatic Medicine : Evidence and Research",

}

TY - JOUR

T1 - Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.

AU - Pan, Jen-Jung

AU - Javle, Milind

AU - Thinn, Mie Mie

AU - Hsueh, Chung-Tzu

AU - Hsueh, Chung-Tsen

PY - 2010/11/2

Y1 - 2010/11/2

N2 - Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.

AB - Sorafenib is an oral multiple kinase inhibitor that blocks Raf, vascular endothelial growth factor receptor, and platelet-derived growth factor receptor. It has been approved in the US and Europe for the treatment of advanced hepatocellular carcinoma (HCC). Sorafenib has demonstrated a 44% increase in survival for advanced HCC patients, compared with best supportive care alone. We have reviewed the pharmacology, pivotal studies, and safety data for this agent. Sorafenib is the first systemic drug demonstrating a significant survival benefit, and is the standard of care for patients with advanced HCC for whom no potential curative option is available.

UR - https://www.dovepress.com/getfile.php?fileID=8035

UR - https://www.mendeley.com/catalogue/726962e2-9c89-3de5-8eac-6e9098438c84/

U2 - 10.2147/HMER.S7123

DO - 10.2147/HMER.S7123

M3 - Review article

C2 - 24367212

VL - 2

SP - 147

EP - 155

JO - Hepatic Medicine : Evidence and Research

JF - Hepatic Medicine : Evidence and Research

ER -

Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.

Abstract

Disciplines

Access to Document

OpenUrl availability

Other files and links

Cite this